HP 129Xe MRI for Evaluation of CLAD in Lung Transplant Recipients (NCT05550662) | Clinical Trial Compass
TerminatedPhase 2
HP 129Xe MRI for Evaluation of CLAD in Lung Transplant Recipients
Stopped: Recruitment challenges
Canada6 participantsStarted 2024-02-07
Plain-language summary
To evaluate the feasibility of hyperpolarized 129Xe MRI in lung transplant recipients and assess structural and functional pulmonary changes using hyperpolarized 129Xe MRI
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients, deemed clinically stable by the lung transplant team at UHN Toronto Lung Transplant Program (TLTP), 18 years of age or older
* Double lung transplant recipient
* For the 5 CLAD-free participants - at least 1 year of follow-up post-LTx and no substantial and persistent FEV1 decline (as per the ISHLT CLAD definition).
* For the 10 participants with CLAD - prior diagnosis of CLAD made by the clinical team (member of the TLTP).
* PFT measurements within 1 month of scan visit.
* FEV1 \> 1.0 L
Exclusion Criteria:
* Currently pregnant or lactating
* Psychiatric or addictive disorders that would preclude obtaining informed consent or adherence to protocol
* Inability to travel to obtain MRI scan
* Any contraindications to MRI including but not limited to severe claustrophobia, implanted devices, aneurysm clips, neurostimulators (patients will be prescreened prior to registration).
* Baseline oxygen saturation of less than 88%.
* Requiring supplemental oxygen at baseline